FDA Approves SGLT2 Inhibitor Ertugliflozin for Type 2 Diabetes

Date: 
December, 2018

December 21, 2017. The US Food and Drug Administration (FDA) has approved the sodium-glucose cotransporter 2 (SGLT-2) inhibitor ertugliflozin for adults with type 2 diabetes (T2D). Ertugliflozin is a once-daily monotherapy available in 2 doses (5 and 15 mg); it also was approved for use in 2 fixed-dose combinations (with sitagliptin or metformin). Its approval was based on 9 phase 3 trials in approximately 12,600 adults with T2D. You can read more here.